Abstract
Forty-six patients with histologically confirmed lung cancer received treatment with the cytotoxic drug VP-16-213 in a dose of 100 mg twice daily, given orally for five days. The overall objective response rate was 11 out of 46 (24%) or 11 of the 33 (33%) who survived to receive two cycles. The drug was effective in all histological types. Only one patient developed leucopenia. This demonstration of the safety of VP-16-213 and its effectiveness suggested that this drug might be used in combination chemotherapy. A series of pilot studies showed unexplained marrow toxicity when VP-16-123 combined with vincristine was given with either methotrexate of adriamycin.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Cavalli F., Sonntag R. W., Jungi F., Senn H. J., Brunner K. W. VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules. Cancer Treat Rep. 1978 Mar;62(3):473–475. [PubMed] [Google Scholar]
- Hansen M., Hirsch F., Dombernowsky P., Hansen H. H. Treatment of small cell anaplastic carcinoma of the lung with the oral solution of VP-16-213 (NSC 141540, 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside). Cancer. 1977 Aug;40(2):633–637. doi: 10.1002/1097-0142(197708)40:2<633::aid-cncr2820400207>3.0.co;2-o. [DOI] [PubMed] [Google Scholar]